Cited by 257Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Modulation of astrocyte reactivity improves functional deficits in mouse models of Alzheimer’s disease

Open access
Ceyzériat, Kelly, Ben Haim, Lucile, Denizot, Audrey, Pommier, Dylan, Matos, Marco, Guillemaud, Océane, Palomares, Marie-Ange, Abjean, Laurene +24 more·2018·Acta Neuropathologica Communications

Abstract

Astrocyte reactivity and neuroinflammation are hallmarks of CNS pathological conditions such as Alzheimer's disease. However, the specific role of reactive astrocytes is still debated. This controversy may stem from the fact that most strategies used to modulate astrocyte reactivity and explore its contribution to disease outcomes have only limited specificity. Moreover, reactive astrocytes are now emerging as heterogeneous cells and all types of astrocyte reactivity may not be controlled efficiently by such strategies.Here, we used cell type-specific approaches in vivo and identified the JAK2-STAT3 pathway, as necessary and sufficient for the induction and maintenance of astrocyte reactivity. Modulation of this cascade by viral gene transfer in mouse astrocytes efficiently controlled several morphological and molecular features of reactivity. Inhibition of this pathway in mouse models of Alzheimer's disease improved three key pathological hallmarks by reducing amyloid deposition, improving spatial learning and restoring synaptic deficits.In conclusion, the JAK2-STAT3 cascade operates as a master regulator of astrocyte reactivity in vivo. Its inhibition offers new therapeutic opportunities for Alzheimer's disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40478-018-0606-1

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Only a subset, often a mix of A1 and A2 or pan-reactive transcripts, are upregulated in astrocytes from brains of study participants with HD or AD, or from several mouse models of acute injuries and chronic diseases of the CNS.

    “Importantly, only a subset, often a mix of A1 and A2 or pan-reactive transcripts, are upregulated in astrocytes from brains of study participants with HD74 or AD75,76, or from several mouse models of acute injuries and chronic diseases of the CNS42,69,76,77.”

    From Reactive astrocyte nomenclature, definitions, and future directions (2021) · cites this paper as [42]

    The Results section (‘SOCS3 normalizes multiple reactive astrocyte markers in AD mice’; page unavailable) reports induced pan-reactive, A1 and A2 markers in astrocytes from an AD mouse model, supporting the mixed-marker portion of the claim. This paper does not establish that pattern in astrocytes from human AD participants or across several models of acute CNS injury and chronic disease. The HD portion is attached to a different citation. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Interventional strategies such as classical pharmacology, genetic manipulation, and biomaterials are available tools to modify pathological signaling in reactive astrocytes for therapeutic purposes.

    “Finally, interventional strategies such as classical pharmacology56,98, genetic manipulation42,56, and biomaterials99 are available tools to modify pathological signaling in reactive astrocytes for therapeutic purposes.”

    From Reactive astrocyte nomenclature, definitions, and future directions (2021) · cites this paper as [42]

    The Discussion section reports that astrocyte-targeted viral gene transfer altered JAK2–STAT3 signaling in Alzheimer’s disease mouse models, supporting genetic manipulation as an intervention. The cited paper does not establish classical pharmacology as a tool for this purpose; the biomaterials example is attached to a different citation. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Manipulation of reactive astrocytes has resulted in improved outcomes, worse outcomes, and no change in mouse models of AD and MS.

    “For example, the manipulation of reactive astrocytes has resulted in improved outcomes38,42,43, worse35 outcomes, and no change44 in mouse models of AD and MS40,45,46.”
  • Blocking astrocyte reactivity has positive effects on AD pathology.

    “On the other hand, blocking astrocyte reactivity has demonstrated positive effects on pathology (Ceyzeriat et al., 2018; Reichenbach et al., 2019).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ceyzériat, K., Ben Haim, L., Denizot, A., Pommier, D., Matos, M., Guillemaud, O., Palomares, M.-A., Abjean, L., Petit, F., Gipchtein, P., Gaillard, M.-C., Guillermier, M., Bernier, S., Gaudin, M., Aurégan, G., Joséphine, C., Déchamps, N., Veran, J., Langlais, V., Cambon, K., Bemelmans, A. P., Baijer, J., Bonvento, G., Dhenain, M., Deleuze, J.-F., Oliet, S. H. R., Brouillet, E., Hantraye, P., Carrillo-de Sauvage, M.-A., Olaso, R., Panatier, A., & Escartin, C.
Affiliations
  • Université Paris-Sud (FR)
  • Université de Bordeaux (FR)
  • Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
Corresponding author
Escartin, Carole
Venue
Acta Neuropathologica Communications
Published
2018-10-16
Volume
6
Issue
1
Pages
104-104
ISSN
2051-5960 (ISSN-L)
OpenAlex
W2897601491
Cited by
256
References
86
Citations by year
2026: 18 · 2025: 38 · 2024: 50 · 2023: 38 · 2022: 30 · 2021: 40 · 2020: 31 · 2019: 11
FWCI
9.22
Type
journal article
Language
en
Open access
Locations
  • Acta Neuropathologica Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Fédération pour la Recherche sur le Cerveau
  • Agence Nationale de la Recherche (2010-JCJC-1402-1; 2011-BSV4-021-03; ANR-16-TERC-0016-01, 2011-INBS-0011)
  • Fondation Vaincre Alzheimer (FR-15015)
  • Association France Alzheimer and Fondation de France
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
astrocyte activation, Alzheimer's disease, JAK2/STAT3 signaling, neuroinflammation, viral gene delivery, amyloid deposition, spatial learning deficits, synaptic dysfunction, therapeutic target
MeSH terms
Suppressor of Cytokine Signaling 3 Protein, Alzheimer Disease, Animals, Apolipoproteins E, Astrocytes, Disease Models, Animal, Glial Fibrillary Acidic Protein, Hippocampus, Male, Mice, Transgenic, Mutation, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Maze Learning, Excitatory Postsynaptic Potentials, Extracellular Signal-Regulated MAP Kinases, STAT1 Transcription Factor, Mice, Janus Kinase 2, Presenilin-1, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review